Science Explorer Back to mapMap
Discussion
Institution · Tropical Disease Foundation

Most cited papers from Tropical Disease Foundation

Tropical Disease Foundation

What are the most cited papers from Tropical Disease Foundation?

The most cited paper from Tropical Disease Foundation is "WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update" (Dennis Falzon et al., 2011), with 1,106 citations. Next come "Feasibility, diagnostic accuracy, and effectiveness of decentralised use of the Xpert MTB/RIF test for diagnosis of tuberculosis and multidrug resistance: a multicentre implementation study" (1,028) and "Delamanid for Multidrug-Resistant Pulmonary Tuberculosis" (748).

Showing 50 of 84 papers. Every paper is listed.

Most cited papers, sortable by citations and release date
#Paper
1 WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update Dennis Falzon et al. · European Respiratory Journal Open access 2 Aug 2011 1,106
2 Feasibility, diagnostic accuracy, and effectiveness of decentralised use of the Xpert MTB/RIF test for diagnosis of tuberculosis and multidrug resistance: a multicentre implementation study Catharina C. Boehme et al. · The Lancet Open access Apr 2011 1,028
3 Delamanid for Multidrug-Resistant Pulmonary Tuberculosis Maria Tarcela Gler et al. · New England Journal of Medicine Open access 7 Jun 2012 748
4 Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis Nafees Ahmad et al. · The Lancet ReviewOpen access108 authors Sep 2018 648
5 Multidrug Resistant Pulmonary Tuberculosis Treatment Regimens and Patient Outcomes: An Individual Patient Data Meta-analysis of 9,153 Patients Shama Desai Ahuja et al. · PLoS Medicine ReviewOpen access 28 Aug 2012 542
6 Rapid Diagnosis of Tuberculosis with the Xpert MTB/RIF Assay in High Burden Countries: A Cost-Effectiveness Analysis Anna Vassall, Sanne Christine van Kampen, Hojoon Sohn et al. · PLoS Medicine Open access 8 Nov 2011 316
7 Prevalence of and risk factors for resistance to second-line drugs in people with multidrug-resistant tuberculosis in eight countries: a prospective cohort study Tracy L. Dalton, Peter Cegielski, Somsak Akksilp et al. · The Lancet Open access 29 Aug 2012 228
8 Efficacy and safety of delamanid in combination with an optimised background regimen for treatment of multidrug-resistant tuberculosis: a multicentre, randomised, double-blind, placebo-controlled, parallel group phase 3 trial Florian von Groote-Bidlingmaier et al. · The Lancet Respiratory Medicine Open access 8 Jan 2019 169
9 Sputum culture conversion as a prognostic marker for end-of-treatment outcome in patients with multidrug-resistant tuberculosis: a secondary analysis of data from two observational cohort studies Ekaterina V. Kurbatova et al. · The Lancet Respiratory Medicine Open access 25 Feb 2015 164
10 Treatment Strategy for Rifampin-Susceptible Tuberculosis Nicholas Iain Paton et al. · New England Journal of Medicine Open access 20 Feb 2023 160
11 Estimating the future burden of multidrug-resistant and extensively drug-resistant tuberculosis in India, the Philippines, Russia, and South Africa: a mathematical modelling study Aditya Sharma et al. · The Lancet Infectious Diseases Open access 9 May 2017 155
12 Shortening Treatment in Adults with Noncavitary Tuberculosis and 2-Month Culture Conversion John L. Johnson, David Jamil Hadad, Reynaldo Dietze et al. · American Journal of Respiratory and Critical Care Medicine Open access 19 Jun 2009 154
13 Predictors of poor outcomes among patients treated for multidrug-resistant tuberculosis at DOTS-plus projects Ekaterina V. Kurbatova, Allison B. Taylor, Victoria M. Gammino et al. · Tuberculosis Open access 10 Jul 2012 154
14 Extensive Drug Resistance Acquired During Treatment of Multidrug-Resistant Tuberculosis J. Peter Cegielski et al. · Clinical Infectious Diseases Open access 23 Jul 2014 150
15 Feasibility and Cost-Effectiveness of Treating Multidrug-Resistant Tuberculosis: A Cohort Study in the Philippines Thelma E. Tupasi, Rajesh Kashi Prakash Gupta, M. I. D. Quelapio et al. · PLoS Medicine Open access 11 Sep 2006 122
16 Efficacy of the adjuvanted subunit protein COVID-19 vaccine, SCB-2019: a phase 2 and 3 multicentre, double-blind, randomised, placebo-controlled trial Lulu C Bravo et al. · The Lancet Open access 2022 113
17 Predicting Extensively Drug-Resistant Mycobacterium tuberculosis Phenotypes with Genetic Mutations Timothy C. Rodwell et al. · Journal of Clinical Microbiology Open access 19 Dec 2013 107
18 Multidrug-Resistant Tuberculosis Treatment Outcomes in Relation to Treatment and Initial Versus Acquired Second-Line Drug Resistance J. Peter Cegielski et al. · Clinical Infectious Diseases Open access 27 Oct 2015 103
19 Estimating the contribution of subclinical tuberculosis disease to transmission: An individual patient data analysis from prevalence surveys Jon C. Emery et al. · eLife Open access 26 Oct 2023 101
20 Novel katG mutations causing isoniazid resistance in clinical M. tuberculosis isolates Jessica Torres, Lynthia V. Paul, Timothy C. Rodwell et al. · Emerging Microbes & Infections Open access 2015 100
21 Factors Associated with Loss to Follow-up during Treatment for Multidrug-Resistant Tuberculosis, the Philippines, 2012–2014 Thelma E. Tupasi, Anna Marie Celina Garfin, Ekaterina V. Kurbatova et al. · Emerging infectious diseases Open access 28 Jan 2016 94
22 Etiology of Acute Lower Respiratory lhlct Infection in Children from Alabang, Metro Manila Thelma E. Tupasi, Marilla Lucero, Dianalyn M. Magdangal et al. · Clinical Infectious Diseases Nov 1990 89
23 Safety and efficacy of the intranasal spray SARS-CoV-2 vaccine dNS1-RBD: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial Fengcai Zhu et al. · The Lancet Respiratory Medicine Open access 15 Nov 2023 74
24 Tuberculosis in the urban poor settlements in the Philippines. Thelma E. Tupasi, S. Radhakrishna, M. I. D. Quelapio et al. · PubMed 2000 67
25 A partially randomised trial of pretomanid, moxifloxacin and pyrazinamide for pulmonary TB Conor Tweed et al. · The International Journal of Tuberculosis and Lung Disease Open access 25 Mar 2021 65
26 Lipoarabinomannan in sputum to detect bacterial load and treatment response in patients with pulmonary tuberculosis: Analytic validation and evaluation in two cohorts Masanori Kawasaki, Carmenchu Echiverri, Lawrence W. Raymond et al. · PLoS Medicine Open access 12 Apr 2019 65
27 Bedaquiline-pretomanid-moxifloxacin-pyrazinamide for drug-sensitive and drug-resistant pulmonary tuberculosis treatment: a phase 2c, open-label, multicentre, partially randomised controlled trial Müge Çevik et al. · The Lancet Infectious Diseases Open access 17 May 2024 62
28 Malnutrition and Acute Respiratory Tract Infections in Filipino Children Thelma E. Tupasi, Nellie V. Mangubat, Ma. Elinor S. Sunico et al. · Clinical Infectious Diseases Nov 1990 60
29 Weight Gain and Response to Treatment for Multidrug-Resistant Tuberculosis Ma Tarcela Gler, Ruffy Guilatco, Janice Campos Caoili et al. · American Journal of Tropical Medicine and Hygiene Open access 10 Sep 2013 60
30 Patterns of Treatment Interruption among Patients with Multidrug-Resistant TB (MDR TB) and Association with Interim and Final Treatment Outcomes Laura Jean Podewils, Maria Tarcela Gler, Maria Imelda Quelapio et al. · PLoS ONE Open access 29 Jul 2013 57
31 Association between Regimen Composition and Treatment Response in Patients with Multidrug-Resistant Tuberculosis: A Prospective Cohort Study Courtney M. Yuen et al. · PLoS Medicine Open access 29 Dec 2015 47
32 Impact of patient and program factors on default during treatment of multidrug-resistant tuberculosis Ma Tarcela Gler, Laura Jean Podewils, N. Munez et al. · The International Journal of Tuberculosis and Lung Disease Open access 14 May 2012 45
33 Evaluation of Pyrosequencing for Detecting Extensively Drug-Resistant Mycobacterium tuberculosis among Clinical Isolates from Four High-Burden Countries Kanchan Ajbani, Shou-Yean Grace Lin, Camilla Rodrigues et al. · Antimicrobial Agents and Chemotherapy Open access 3 Nov 2014 42
34 Bacillary disease and health seeking behavior among Filipinos with symptoms of tuberculosis: implications for control. Thelma E. Tupasi, S. Radhakrishna, V M Co et al. · PubMed Dec 2000 38
35 The effect of household poverty on tuberculosis Andrew M. Siroka, Irwin Law, James A. Macinko et al. · The International Journal of Tuberculosis and Lung Disease Open access 22 Nov 2016 37
36 Multidrug-resistant tuberculosis treatment failure detection depends on monitoring interval and microbiological method Carole Diane Mitnick et al. · European Respiratory Journal Open access Sep 2016 36
37 Analysis of Gender Roles in Philippine Fishing Communities Elin C. Torell, Joan Regina Castro, Alfredo Lazarte et al. · Journal of International Development Open access 17 Nov 2020 34
38 Significant decline in the tuberculosis burden in the Philippines ten years after initiating DOTS. Thelma E. Tupasi, S. Radhakrishna, J A Chua et al. · PubMed Oct 2009 33
39 Inclusion of information on risk factors, socio-economic status and health seeking in a tuberculosis prevalence survey. Knut Lönnroth, Timothy H. Holtz, Frank G. J. Cobelens et al. · PubMed Feb 2009 31
40 BCG coverage and the annual risk of tuberculosis infection over a 14-year period in the Philippines assessed from the Nationwide Prevalence Surveys. Thelma E. Tupasi, S. Radhakrishna, M L Pascual et al. · PubMed Mar 2000 31
41 Diagnosis and management of tuberculosis by private practitioners in Manila, Philippines Christian Auer, Jaime Y. Lagahid, Marcel Tanner et al. · Health Policy 16 Aug 2005 28
42 Geographical Differences Associated with Single-Nucleotide Polymorphisms (SNPs) in Nine Gene Targets among Resistant Clinical Isolates of Mycobacterium tuberculosis Matt Hoshide, Lishi Qian, Camilla Rodrigues et al. · Journal of Clinical Microbiology Open access 20 Jun 2013 27
43 Clinical symptoms and microbiological outcomes in tuberculosis treatment trials Chung Wung Bark, Reynaldo Dietze, Alphonse Okwera et al. · Tuberculosis Open access 7 Aug 2011 24
44 Population-wide active case finding as a strategy to end TB Thu Anh Nguyen, Alvin Kuo Jing Teo, Yanlin Zhao et al. · The Lancet Regional Health - Western Pacific Open access 22 Mar 2024 22
45 DOTS-Plus for multidrug-resistant tuberculosis in the Philippines: global assistance urgently needed Thelma E. Tupasi, M. I. D. Quelapio, Ruth B Orillaza et al. · Tuberculosis Feb 2003 22
46 Measuring socio-economic data in tuberculosis prevalence surveys Frank van Leth, Ruffy Guilatco, Sheikh Jamal Hossain et al. · The International Journal of Tuberculosis and Lung Disease 9 May 2011 21
47 Multidrug-resistant tuberculosis among previously treated patients in the Philippines Maria Tarcela Gler, L. E. Macalintal, Lawrence W. Raymond et al. · The International Journal of Tuberculosis and Lung Disease 11 Apr 2011 19
48 Genotypic characteristics of Mycobacterium tuberculosis isolated from household contacts of tuberculosis patients in the Philippines Irene G. Sia, Seanne P. Buckwalter, Kelly A. Doerr et al. · BMC Infectious Diseases Open access Dec 2013 18
49 Responding to the multidrug-resistant tuberculosis crisis: mainstreaming programmatic management to the Philippine National Tuberculosis Programme. M. I. D. Quelapio, Nona Rachel C. Mira, Ruth Orillaza-Chi et al. · PubMed Jun 2010 17
50 Bacteriologic monitoring of multidrug-resistant tuberculosis patients in five DOTS-Plus pilot projects Victoria M. Gammino, Allison B. Taylor, Michael Rich et al. · The International Journal of Tuberculosis and Lung Disease 26 Sep 2011 17

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.